Modality
ASO
MOA
BETi
Target
BCL-2
Pathway
Neuroinflam
CFADHDSchizophrenia
Development Pipeline
Preclinical
~Jul 2016
→ ~Oct 2017
Phase 1
Jan 2018
→ Jun 2028
Phase 1Current
NCT03092554
2,939 pts·CF
2024-05→2028-06·Not yet recruiting
NCT06405294
1,412 pts·Schizophrenia
2018-01→2025-02·Recruiting
4,351 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-02-191.1y agoInterim· Schizophrenia
2028-06-082.2y awayInterim· CF
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P1
Recruit…
P1
Not yet…
Catalysts
Interim
2025-02-19 · 1.1y ago
Schizophrenia
Interim
2028-06-08 · 2.2y away
CF
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03092554 | Phase 1 | CF | Not yet recr... | 2939 | SeizFreq |
| NCT06405294 | Phase 1 | Schizophrenia | Recruiting | 1412 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| ARG-4339 | Argenx | Phase 2 | BCL-2 | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| GMA-729 | Genmab | Phase 2 | BCL-2 |